List of Excipients in Branded Drug SELENIUM SULFIDE

Generic Drugs Containing SELENIUM SULFIDE

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	selenium sulfide	45802-040	BENTONITE
Padagis Israel Pharmaceuticals Ltd	selenium sulfide	45802-040	CITRIC ACID MONOHYDRATE
Padagis Israel Pharmaceuticals Ltd	selenium sulfide	45802-040	GLYCOL STEARATE

What are the Most Frequently-Used Excipients in SELENIUM SULFIDE?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
8	BENTONITE
3	CAPTAN

Selenium Sulfide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Selenium sulfide is a mature topical active with limited molecule-level exclusivity and continuing commercial value in dandruff, seborrheic dermatitis, pityriasis versicolor, and related scalp disorders. The strongest product opportunities are formulation-led: stable suspensions, improved cosmetic sensory properties, low-residue shampoos, higher-use-convenience systems, and differentiated packaging. Excipient selection must control selenium sulfide sedimentation, wetting, odor, color, viscosity, microbial risk, and removal from hair and skin.

What products contain selenium sulfide?

Selenium sulfide is marketed primarily in topical shampoos, lotions, suspensions, and scalp treatments.

Product category	Typical strength	Regulatory positioning	Main use
OTC dandruff shampoo	1.0%	OTC monograph-based or legacy marketed product, depending on jurisdiction	Dandruff and seborrheic dermatitis
Prescription lotion or shampoo	2.5%	Prescription drug product	Seborrheic dermatitis, tinea versicolor, related conditions
Generic prescription suspension	2.5%	Abbreviated or legacy generic pathway	Substitution for branded prescription products
Veterinary topical product	Varies by market	Animal-health regulation	Dermatologic and cleansing applications
Combination or specialty scalp product	Varies	Drug, cosmetic, or combination classification	Dandruff, scalp cleansing, cosmetic positioning

In the United States, selenium sulfide is recognized as an active ingredient for dandruff, seborrheic dermatitis, and psoriasis-related OTC products under the FDA topical acne, dandruff, seborrheic dermatitis, and psoriasis framework. The FDA OTC monograph identifies selenium sulfide at 1% as an established active ingredient for dandruff and seborrheic dermatitis products. Prescription products commonly use 2.5% selenium sulfide. [1,2]

Known commercial references include Selsun Blue and generic selenium sulfide 2.5% products. Product availability, ownership, labeling, and marketing status vary by country and distributor.

What excipient properties are critical for selenium sulfide formulations?

Selenium sulfide is practically insoluble in water and must generally be formulated as a dispersed solid rather than a true solution. The excipient system therefore determines dose uniformity, physical stability, application feel, and product appearance.

The main formulation risks are:

1. Sedimentation and hard caking.
2. Poor wetting and floating particles.
3. Inconsistent dose per use.
4. Abrasive or gritty texture.
5. Excessive scalp or hair residue.
6. Selenium sulfide odor or color.
7. Preservative failure in a water-rich system.
8. Viscosity changes during storage.
9. Packaging incompatibility.
10. Difficulty removing the product after treatment.

A successful formulation should maintain a uniform suspension after storage and normal consumer handling. It must redisperse with modest shaking and deliver a reproducible amount of active during each use.

Particle size and suspension control

Particle engineering is the central excipient issue. Smaller and more uniform particles can improve texture and reduce visible sedimentation, but excessive milling can increase surface energy, agglomeration, oxidation risk, or manufacturing complexity.

Relevant controls include:

• Particle-size distribution.
• Crystal or amorphous state.
• Bulk density.
• Sedimentation volume.
• Redispersibility after accelerated storage.
• Wetting time.
• Microscopic agglomerate size.
• Assay uniformity across the container.

Suspending agents can include cellulose derivatives, carbomers, clays, gums, and synthetic rheology modifiers. The target is a structured vehicle with sufficient low-shear viscosity to slow settling, while retaining shear-thinning behavior during shaking and dispensing.

High viscosity alone is not a solution. A vehicle that is too thick can reduce consumer acceptance, impair spreadability, complicate filling, and leave visible residue on hair.

Wetting and dispersing agents

Selenium sulfide requires effective wetting before it can be uniformly dispersed. Surfactants and polymeric dispersants can reduce floating, agglomeration, and localized concentration.

Potential excipient classes include:

• Anionic surfactants for cleansing and foam.
• Amphoteric surfactants for milder scalp feel.
• Nonionic surfactants for wetting and compatibility.
• Polymeric dispersants for particle stabilization.
• Solubilizers for fragrance or auxiliary ingredients.
• Co-surfactants to improve rinsability.

The surfactant system must be evaluated against scalp irritation, foam profile, active adsorption, preservative performance, and particle redispersion. A high-foam shampoo may improve consumer perception but can increase formulation complexity and rinse time.

What excipients improve selenium sulfide shampoo performance?

Cleansing and sensory system

A shampoo platform normally requires a balance of cleansing power, foam, wet combing, and rinseability. Anionic surfactants can provide strong cleansing, while amphoteric surfactants can reduce harshness and improve foam stability.

Cationic conditioning polymers may improve hair feel but can interact with anionic surfactants or suspended particles. They may also increase deposition and leave a film that reduces cosmetic acceptance. Conditioning agents should be screened for:

• Wet and dry combing.
• Hair deposition.
• Active recovery from the scalp.
• Rinse residue.
• Viscosity drift.
• Compatibility with preservatives and fragrance.

A low-residue system is commercially attractive because selenium sulfide products can be associated with visible scalp or hair residue and an unpleasant medicinal experience.

Rheology modifiers

Cellulosic polymers, carbomers, xanthan gum, clays, and synthetic acrylic polymers each create different suspension and sensory profiles.

Excipient class	Commercial benefit	Main risk
Hydroxyethylcellulose or related cellulose polymers	Mild thickening and broad compatibility	Stringiness, viscosity loss, microbial burden
Xanthan gum	Strong suspension support	Tacky feel and poor clarity
Carbomer	Efficient low-use-level rheology	Electrolyte sensitivity and pH dependence
Clay minerals	Suspension and sensory modification	Grittiness, color, processing variability
Acrylic rheology modifiers	Tunable texture and shear thinning	Neutralization requirements and compatibility issues
Polymer blends	Better balance of suspension and spreadability	Higher development and scale-up complexity

The preferred rheology profile is usually pseudoplastic. The product should remain stable in the bottle, flow under dispensing, spread over wet hair, and rinse without excessive residue.

Preservatives and water activity

Most selenium sulfide shampoos and lotions are aqueous systems. Preservative selection must account for surfactants, polymers, pH, packaging, and microbial challenge results.

Preservative programs may use combinations of approved antimicrobial agents, chelators, and pH control. Chelators can improve preservative robustness by reducing metal-catalyzed degradation and limiting microbial access to trace nutrients. The system must be assessed through preservative effectiveness testing under the applicable pharmacopoeial method.

Preservative selection is commercially important for multidose packages. A pump or metered dispenser can reduce contamination compared with a wide-mouth jar, but the packaging must be compatible with the suspension and capable of dispensing a consistent dose.

What pH and packaging strategy is appropriate?

The formulation pH should support scalp tolerability, preservative activity, polymer performance, surfactant stability, and active suspension. A mildly acidic to near-neutral system is often attractive for scalp products, but the final pH must be established through stability and compatibility testing rather than selected solely for cosmetic reasons.

Packaging should limit contamination, control evaporation, and support redispersion. Suitable formats include:

• Inverted squeeze bottles.
• Dispensing closures.
• Metered pumps.
• Unit-dose sachets.
• Airless or low-air-intrusion systems for specialty lotions.

Opaque or light-protective packaging may support appearance stability where the formulation contains light-sensitive excipients, dyes, fragrance components, or polymer systems. The packaging must also prevent leakage and allow the label to communicate the need to shake the product when required.

A bottle with poor sedimentation behavior can create dose variability even when the bulk formulation passes initial release testing. Commercial development should therefore include simulated consumer handling, including storage upright and inverted, partial use, repeated shaking, and dispensing near the end of the container.

What formulation patents protect selenium sulfide products?

Selenium sulfide has been used in topical products for decades. The active ingredient is therefore unlikely to provide meaningful new-molecule exclusivity for a modern developer. Commercial protection is more likely to arise from formulation, delivery, manufacturing, packaging, or method-of-use claims.

Potentially protectable subject matter includes:

• Narrow particle-size distributions.
• Stabilized selenium sulfide suspensions.
• Specific polymer and surfactant combinations.
• Low-residue or low-odor vehicles.
• Controlled-release scalp systems.
• Foam or aerosol delivery.
• Combination products with antifungal or keratolytic actives.
• Metered-dose packaging.
• Improved redispersion systems.
• Manufacturing processes that reduce agglomeration.
• Products designed for treatment of pityriasis versicolor or seborrheic dermatitis.

A patent strategy should distinguish between composition claims and performance claims. A broad claim covering selenium sulfide in a shampoo vehicle may face prior-art pressure. A narrower claim tied to particle size, suspension stability, redispersibility, reduced residue, or a defined excipient ratio may have better differentiation if supported by comparative data.

How strong is the selenium sulfide patent estate?

The estate is generally stronger for incremental formulation innovation than for the active ingredient itself. Key strength factors are:

Patent factor	Likely assessment
Active-ingredient exclusivity	Weak because of long commercial history
Broad shampoo composition claims	Vulnerable to prior art
Defined suspension architecture	Potentially stronger
Particle engineering claims	Stronger when linked to measurable performance
Packaging claims	Moderate, depending on dispensing advantage
Manufacturing claims	Potentially valuable if difficult to design around
Method-of-use claims	Moderate, but dependent on treatment scope and prior art
Combination-product claims	Variable and dependent on clinical differentiation
Trade-secret manufacturing know-how	Often commercially important

A freedom-to-operate review should search U.S., European, Japanese, Chinese, and major emerging-market records for selenium sulfide, selenium disulfide, suspension, shampoo, lotion, dandruff, seborrheic dermatitis, tinea versicolor, particle size, and redispersibility claims.

What is the FDA regulatory status of selenium sulfide?

The FDA recognizes selenium sulfide as an established topical active for dandruff and seborrheic dermatitis products within the OTC framework. The regulatory pathway depends on concentration, labeling, dosage form, claims, and whether the product fits the applicable monograph conditions. [1]

Prescription 2.5% products require an approved drug application or an applicable abbreviated pathway. The regulatory package must address:

• Identity and assay of selenium sulfide.
• Particle-size controls.
• Content uniformity.
• Microbial limits.
• Preservative effectiveness.
• Viscosity and rheology.
• Redispersibility.
• Stability.
• Container-closure compatibility.
• In-use performance.
• Labeling and warnings.

A new excipient, unusual delivery system, or materially different formulation can increase regulatory burden even when the active is well established. A generic developer should avoid unnecessary formulation complexity unless it creates a clear regulatory, commercial, or patent advantage.

What is the Orange Book status of selenium sulfide products?

FDA Orange Book treatment is product-specific and depends on the listed NDA or ANDA, dosage form, and current marketing status. Selenium sulfide prescription products may have historical NDA and ANDA records, but the existence and status of a specific listing must be verified in the current FDA Orange Book database. [3]

For business planning, the relevant questions are:

• Whether the reference listed drug is currently marketed.
• Whether patents or exclusivity are listed.
• Whether an ANDA can rely on the product as the reference.
• Whether the listed product has an active therapeutic-equivalence code.
• Whether a product-specific labeling or formulation difference affects substitution.

Because selenium sulfide is an old active, generic entry risk is usually driven more by formulation equivalence, manufacturing capability, distribution, and market concentration than by new chemical entity exclusivity.

When does selenium sulfide lose exclusivity?

Selenium sulfide has no meaningful remaining new-molecule exclusivity in the conventional U.S. sense. The relevant commercial barriers are product-specific patents, regulatory exclusivity, trademarks, manufacturing know-how, and channel access.

Exclusivity type	Relevance to selenium sulfide
New chemical entity exclusivity	Generally not relevant
Orphan exclusivity	Not a primary commercial feature
Pediatric exclusivity	Product-specific and unlikely to drive the category
Formulation patents	Potentially relevant
Method-of-use patents	Potentially relevant
Trademark protection	Important for branded OTC products
Manufacturing know-how	Important for suspension quality
Retail shelf position	Often more important than patent life

Branded OTC products can maintain pricing through consumer recognition, packaging, distribution, and perceived cosmetic superiority. Prescription products face greater substitution pressure because the active is mature and generic formulations are available.

Which companies are competing in selenium sulfide?

Competition spans branded OTC manufacturers, generic prescription manufacturers, contract manufacturers, and private-label distributors.

The commercial field includes:

• Branded dandruff-care companies.
• Generic pharmaceutical manufacturers.
• Retail pharmacy private-label suppliers.
• Dermatology-focused companies.
• Contract development and manufacturing organizations.
• Veterinary-health companies.
• International manufacturers serving markets where selenium sulfide remains common.

The strongest competitive differentiation is likely to come from product experience rather than active-ingredient novelty. Relevant attributes include fragrance, foam, rinsability, residue, scalp comfort, package usability, treatment frequency, and visible control of flaking.

What commercial opportunities exist for selenium sulfide?

Premium OTC scalp-care products

A 1% OTC product can be positioned around improved tolerability, lower residue, better fragrance, reduced treatment time, or a more attractive package. The regulatory advantage is the established active and familiar consumer indication.

Potential concepts include:

• Fragrance-reduced or fragrance-free shampoo.
• Sensitive-scalp formulation.
• Clearer or less visibly colored product.
• Low-residue formulation for textured or treated hair.
• Travel-size and single-use packaging.
• Combination scalp-care product with conditioning benefits.
• Dermatologist-positioned private-label product.

Prescription generic and authorized-generic products

A 2.5% product may offer a relatively straightforward generic opportunity where the reference product is active and substitutable. The principal development risk is physical equivalence. Selenium sulfide products can differ materially in particle size, viscosity, odor, color, and redispersibility while appearing similar on paper.

A developer with reliable suspension manufacturing can compete through:

• Lower cost of goods.
• Consistent supply.
• Smaller minimum batch sizes.
• Improved package design.
• Private-label distribution.
• International registration packages.

Tinea versicolor and dermatology specialty products

Selenium sulfide is used in topical treatment regimens for pityriasis versicolor. A product designed around easier application over large skin areas could have value, particularly if it reduces mess, contact-time burden, or residue.

Potential delivery systems include:

• Spreadable lotions.
• Foams.
• Pump sprays.
• Premeasured applicators.
• Wash-off gels.
• Scalp-and-body formulations.

Any new claim would require regulatory substantiation and must remain within the permitted labeling framework for the target jurisdiction.

Veterinary opportunities

Veterinary selenium sulfide products can target seborrheic skin conditions, scaling, odor, and coat cleansing. Animal-health formulations may permit different sensory and packaging priorities, but they still require species-specific safety, labeling, and quality controls.

What generic launch risks exist?

The highest generic launch risks are operational rather than patent-driven.

Risk	Business impact	Mitigation
Caking during storage	Dose inconsistency and complaints	Optimize particle size and suspension network
Poor wetting	Floating or clumped active	Use validated wetting and dispersion process
Excessive residue	Low repeat use and retailer rejection	Screen surfactant and polymer system
Color instability	Product rejection	Control raw material, light, and packaging
Preservative failure	Recall or regulatory action	Challenge testing and robust package design
Variable viscosity	Filling and consumer-use problems	Define rheology specifications
Inadequate shaking	Uneven dose	Improve redispersion and labeling
Supply concentration	Margin pressure	Qualify multiple active and excipient sources
Weak retail differentiation	Low pricing power	Use sensory and packaging advantages
Limited medical differentiation	Prescriber substitution	Target adherence and application convenience

How should an R&D team prioritize excipient development?

The most efficient development sequence is:

1. Characterize the selenium sulfide raw material and particle-size distribution.
2. Select a small set of wetting and dispersing systems.
3. Build suspension matrices across several rheology profiles.
4. Screen pH, preservative, surfactant, and conditioning-polymer compatibility.
5. Test redispersibility after accelerated and long-term storage.
6. Assess hair and scalp residue using standardized sensory and instrumental methods.
7. Select packaging based on dose consistency and in-use stability.
8. Conduct comparative performance testing against the reference product.
9. Lock critical material attributes and process parameters.
10. Develop patent claims around demonstrated performance differences.

The best commercial platform is unlikely to be the thickest or most sophisticated formulation. It is the simplest system that provides stable dispersion, reproducible dosing, acceptable sensory performance, and scalable manufacturing.

Key Takeaways

• Selenium sulfide is a mature topical active with limited molecule-level exclusivity.
• Formulation value is concentrated in suspension stability, particle engineering, rinsability, residue control, and packaging.
• OTC 1% products offer branded, private-label, and premium scalp-care opportunities.
• Prescription 2.5% products offer generic opportunities, with physical equivalence as a central development issue.
• Broad selenium sulfide composition claims face substantial prior-art pressure.
• Narrow claims covering particle size, redispersibility, excipient ratios, packaging, or manufacturing may offer stronger protection.
• Commercial success depends heavily on cosmetic acceptability, supply reliability, and retail or pharmacy distribution.
• The most attractive R&D path is a stable, low-residue, easy-to-use suspension with measurable performance advantages.

FAQs

Can selenium sulfide be formulated as a clear solution?

Usually not through conventional aqueous formulation because selenium sulfide has very low water solubility. A dispersed suspension is the more practical platform.

Which excipients are most important for selenium sulfide stability?

Suspending agents, wetting agents, surfactants, preservatives, chelators, pH adjusters, and packaging materials have the greatest effect on product stability and dose uniformity.

Is selenium sulfide suitable for a foam product?

A foam may improve application to the scalp or body, but the formulation must maintain uniform active distribution during foaming, storage, dispensing, and use.

Can a selenium sulfide product obtain new patent protection?

Yes, potentially through formulation, particle engineering, delivery, packaging, manufacturing, or method-of-use claims. The claims must provide novelty and an inventive technical effect over prior art.

Is selenium sulfide a strong candidate for a premium OTC product?

Yes, if the product improves odor, residue, rinseability, scalp feel, packaging convenience, or treatment adherence. The active itself is unlikely to support premium pricing without a differentiated user experience.

References

1. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 358: Requirements for specific active ingredients used in over-the-counter human drug products. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2022). OTC Monograph M032: Topical antimicrobial drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

5. European Medicines Agency. (2019). Guideline on quality of topical products. EMA.